Zomedica Partners with Boehringer Ingelheim Animal Health Canada to Expand Truforma Equine Endocrine Testing in Canada

Zomedica Schedules “Fourth Friday at Four” Investor Webinar on International Expansion Strategy

Zomedica FY26 Q2 Net Loss Narrows 49% to $3.77 Million; Revenue Rises 37% to $9.51 Million

Zomedica Launches PulseVet Acoustic Muffler Accessory for Shock Wave System

Zomedica shareholders reject executive pay proposal at annual meeting

Zomedica to host “Fourth Friday at Four” investor webinar on Five Pillars strategy framework

Zomedica SVP Sales Kevin Klass reports acquisition of 104,000 common shares worth $10,712

Zomedica director Johnny D. Powers reports buying 200,000 common shares for $20,600

Zomedica SVP Sales Kevin Klass reports buying 216,899 shares for $22,786.69

Seagate, Schwab, Zomedica, Constellation, Lumentum Shake Markets

Zomedica director Johnny D. Powers reports $31,700 common share purchase

Zomedica Director Johnny D. Powers acquires 500,000 shares for $56,201

HPE, Charles Schwab, Zomedica, Illumina, Circle Insider Shake-Up

Zomedica CEO Larry Heaton buys 250,000 shares for $27,500

Zomedica Q1 FY26 net loss narrows 93% to $4.53 million; revenue rises 35% to $8.8 million

Zomedica to host “Fourth Friday at Four” investor webinar on manufacturing operations

Zomedica announces annual shareholder meeting notice

Zomedica Collaborates With Boehringer Ingelheim to Expand Equine PPID Testing on TRUFORMA

Zomedica FY 2025 net loss widened 74% to USD 81.86 million on revenue up 17% to USD 32.03 million

Zomedica to host investor webinar reviewing 2025 results and equine market opportunity